Investing

Cytokinetics : CYTK

CYTK

Stock Data

$63.35

$0.62 (0.97%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Cytokinetics Inc is a biopharmaceutical company based in South San Francisco, California, dedicated to the development and potential commercialization of muscle activators and inhibitors for treating serious diseases. With a focus on small molecule drug candidates, Cytokinetics is advancing a diverse portfolio, including treatments for heart failure and hypertrophic cardiomyopathy. Their leading drugs in development, such as omecamtiv mecarbil and aficamten, are in late-stage clinical trials, showcasing the company's commitment to addressing unmet medical needs in muscle function and contractility.

All Cytokinetics Articles

4 Articles

Lee Jackson | Dec 27, 2022 at 8:44 AM EST

Tuesday’s Top Analyst Upgrades and Downgrades: CarMax, Caterpillar, Cleveland-Cliffs, Eaton, First Solar, Medical Properties Trust, Paramount Global, Tesla and More

Tuesday's top analyst upgrades and downgrades included Array Technologies, CarMax, Caterpillar, Cleveland-Cliffs, Eaton, First Solar, Intercontinental Exchange, Medical Properties Trust,…

Lee Jackson | Dec 21, 2022 at 8:48 AM EST

Wednesday’s Top Analyst Upgrades and Downgrades: Apple, Caterpillar, Costco, Hasbro, Rivian, Tapestry, Walmart and More

Wednesday's top analyst upgrades and downgrades included Apple, Boston Scientific, Caterpillar, Ciena, Costco Wholesale, Generac, Hasbro, Rivian Automotive, Steel Dynamics,…

Lee Jackson | Jul 20, 2021 at 8:52 AM EDT

Tuesday’s Top Analyst Upgrades and Downgrades: Cloudflare, Con Edison, Ford, IBM, Incyte, Simon Properties, Skechers and More

Tuesday's top analyst upgrades and downgrades included Bank of New York Mellon, Cloudflare, Consolidated Edison, Ford, IBM, Incyte, Simon Properties…

Paul Ausick | Feb 18, 2021 at 2:21 PM EST

Seagate, Micron, Invitae and More Thursday Afternoon Analyst Calls

Here's the Thursday afternoon edition of analysts' upgrades, downgrades and price target changes on several popular stocks.